Paper Details

  1. Home
  2. Paper Details

Lack of irritative potential of nadifloxacin 1% when combined with other topical anti-acne agents.

Author: NeumeisterC, SchwantesU, WilhelmD, WilhelmK P, ZsoltI

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Many different acne treatments exist, with topical therapies being standard for mild to moderate cases. However, combining multiple topical medications can increase skin irritation. While acne has various causes, combining different agents that target different aspects of acne can improve effectiveness and speed up results. This approach is especially important for preventing the development of antibiotic resistance.
Paper Details　
Original Abstract of the Article :
Diverse options are available for the treatment of acne. Topical therapy is standard, especially in cases of mild to moderate acne, while the current treatments for acne vulgaris are topical keratolytics and topical antibiotics. Tolerability is a critical factor in patient compliance with topical ac...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1365-2230.2011.04214.x

データ提供：米国国立医学図書館（NLM）

Nadifloxacin: A Gentle Approach to Acne Treatment

This study investigated the irritative potential of nadifloxacin 1% when combined with other topical anti-acne agents. The researchers aimed to determine whether the combination of nadifloxacin with other topical acne treatments would lead to increased irritation or adverse effects.

The study found that nadifloxacin 1% did not exhibit any significant irritative potential when combined with other topical anti-acne agents. This suggests that nadifloxacin can be safely incorporated into combination therapies for acne, offering patients a potentially more effective treatment option without compromising skin tolerance.

Acne Treatment: Finding the Right Balance

The study emphasizes the importance of considering skin tolerance and potential irritative effects when developing combination therapies for acne. Nadifloxacin 1% appears to be a safe and effective option for combination therapy, offering a potentially more effective approach to treating acne while minimizing the risk of skin irritation. It's like balancing the needs of a delicate desert ecosystem, where finding the right combination of elements can create a thriving and healthy environment.

Minimizing Side Effects: A Key to Patient Compliance

The study's findings underscore the importance of minimizing side effects and maximizing patient compliance in acne treatment. By demonstrating the safety and effectiveness of nadifloxacin 1% in combination therapies, the researchers contribute to the development of more tolerable and effective treatments for this common skin condition.

Dr.Camel's Conclusion

This study provides valuable insights into the safety and tolerability of nadifloxacin 1% when combined with other topical anti-acne agents. The findings suggest that nadifloxacin can be safely incorporated into combination therapies, offering a potentially more effective and well-tolerated treatment option for acne. The study underscores the importance of considering skin tolerance and patient compliance when developing acne treatments.

Date :
  1. Date Completed 2012-05-30
  2. Date Revised 2014-11-20
Further Info :

Pubmed ID

22103435

DOI: Digital Object Identifier

10.1111/j.1365-2230.2011.04214.x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.